Tizanidine extended release - Sun PharmaAlternative Names: SPARC 1401; Tizanidine ER
Latest Information Update: 13 Oct 2016
At a glance
- Originator Sun Pharma Advanced Research Company
- Class Antispastics; Imidazolines; Muscle relaxants; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Musculoskeletal pain
Most Recent Events
- 13 Oct 2016 Sun Pharma Advanced Research Company completes a phase-II trial in Musculoskeletal pain (In volunteers) in Netherlands (EudraCT2015-003770-32) prior to October 2016
- 20 Sep 2016 Sun Pharma Advanced Research Company plans a phase II trial for Back pain in USA (NCT02887534)